MaaT Pharma announces the presentation of two posters for MaaT013 and MaaT033 at the next ASH conference
• The first poster will present the results of 111 patients with acute graft-versus-host disease (aGvHD) treated with MaaT013 as part of the Early Access Program (EAP).
• The second poster will detail the randomized, double-blind Phase 2b clinical trial evaluating MaaT033 in improving the survival of patients receiving an allogeneic hematopoietic stem cell transplant.
• This is the seventh consecutive year that MaaT Pharma abstracts have been selected for presentation at the ASH annual meeting, thus strengthening the Company’s leadership in the field of microbiota in hemato-oncology.
To receive all financial information from MaaT Pharma in real time and for any questions, you can contact us via the following address: [email protected]